Tasiamide B is also a β-secretase 1 (BACE1) inhibitor, with an IC50 value of 0.19 uM against BACE1 [158], has the potential to target Alzheimer’s disease, as BACE1 is involved in abnormal β-amyloid plaque production. The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.